Summary:
Methotrexate (MTX) is commonly used in the prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In order to evaluate the efficacy and safety of low-dose MTX treatment in patients with GVHD after allo-HSCT, 38 patients with acute GVHD (aGVHD), chronic GVHD (cGVHD) or GVHD post-donor lymphocyte infusion (post-DLI GVHD) after allo-HSCT received intravenous MTX at a dose of 5 or 10 mg every 5–7 days until a complete or partial response was seen, or there was treatment failure or intolerable side effects. The overall response rate was 94.7% (18/19 patients) in patients with aGVHD, 76.2% (16/21 patients) in patients with cGVHD and 2/2 in patients with post-DLI GVHD. The response rate for GVHD involving various organs was 100% in skin, 75% in gut, 55.6% in liver, 75% in mouth and 100% in the eye, among all enrolled patients. Side effects were minor. Short-term, low-dose MTX is a tolerable and an effective regimen for patients with aGVHD, cGVHD or post-DLI GVHD after allo-HSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980; 69: 204–217.
Lee SJ, Klein JP, Barrett J et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.
Weisdorf D, Haak R, Blazar B et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.
Sullivan KM, Witherspoon RP, Storb R et al. Alternating day cyclosporine and prednisone for treatment of high risk chronic graft versus host disease. Blood 1988; 72: 555–561.
Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft versus host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.
Willenbacher W, Basara N, Blau IW et al. Treatment of steroid refractory acute and chronic graft versus host disease with daclizumab. Br J Haematol 2001; 112: 820–823.
Parker PM, Chao N, Nadamanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604–3609.
Mookerjee B, Altomonte V, Vogelsang G . Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517–520.
Storb R, Deeg HJ, Fisher L et al. Cyclosporine vs methotrexate for graft-versus-host disease prevention in patients given marrow graft for leukemia: long-term follow-up of three controlled trial. Blood 1988; 71: 293–298.
Rinden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 81: 1094–1101.
Gaziev D, Lucarelli G, Polchi P et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. Bone Marrow Transplant 2001; 27: 45–51.
Martin P, Bleyzac N, souillet G et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881–887.
Koga Y, Nagatoshi Y, Okamura J . Methotrexate vs cyclosporin A as single agent fro graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Bone Marrow Transplant 2003; 32: 171–176.
Huang XJ, Han W, Xu LP et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J (Engl) 2004; 117: 1778–1785.
Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832–843, 895–902.
Wingard JE, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft versus host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, XJ., Jiang, Q., Chen, H. et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36, 343–348 (2005). https://doi.org/10.1038/sj.bmt.1705034
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705034
Keywords
This article is cited by
-
Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation
Journal of Pharmaceutical Health Care and Sciences (2023)
-
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Bone Marrow Transplantation (2021)
-
State-of-the-art acute and chronic GVHD treatment
International Journal of Hematology (2015)
-
Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation
Annals of Hematology (2014)
-
Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility
Bone Marrow Transplantation (2011)